Longitudinal hysteroscopic follow-up during tamoxifen treatment

Tamoxifen, which is the first treatment choice for postmenopausal women with breast cancer, is examined. A study found that in women on tamoxifen for up to 6 years versus longer than 6 years, there was a trend towards developing intrauterine lesions.

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 1998-01, Vol.351 (9095), p.36-36
Main Authors: Neven, P, De Muylder, X, Van Belle, Y, Van-Hooff, I, Vanderick, G
Format: Article
Language:English
Subjects:
Antineoplastic Agents, Hormonal - adverse effects
Antineoplastic Agents, Hormonal - therapeutic use
Biological and medical sciences
Breast cancer
Breast Neoplasms - drug therapy
Cohort Studies
Drug therapy
Endometrial Hyperplasia - chemically induced
Endometrial Hyperplasia - epidemiology
Endometrial Neoplasms - chemically induced
Endometrial Neoplasms - epidemiology
Female
Follow-Up Studies
Gynecology. Andrology. Obstetrics
Humans
Hysteroscopy
Mammary gland diseases
Medical sciences
Menopause
Postmenopause
Risk Factors
Tamoxifen - adverse effects
Tamoxifen - therapeutic use
Time Factors
Tumors
Women
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tamoxifen, which is the first treatment choice for postmenopausal women with breast cancer, is examined. A study found that in women on tamoxifen for up to 6 years versus longer than 6 years, there was a trend towards developing intrauterine lesions.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(05)78091-0